What is the treatment for Behcet's disease?

Treatment of Behçet's Disease

Organ-Specific Treatment Algorithm

Treatment of Behçet's disease must be tailored to the specific organ system involved, with aggressive immunosuppression required for sight-threatening, neurological, vascular, and gastrointestinal manifestations to prevent irreversible damage and death. 1

Mucocutaneous and Joint Involvement

Colchicine 1-2 mg/day is the first-line treatment for arthritis and mucocutaneous lesions, particularly effective in women. 2

• Colchicine has proven efficacy in two randomized controlled trials for arthritis and erythema nodosum 2
• Topical corticosteroids can be applied for orogenital ulcerations 3
• NSAIDs provide minimal benefit for arthritic symptoms 3

Ocular Involvement (Posterior Segment Disease)

Any patient with posterior segment eye disease must receive azathioprine combined with systemic corticosteroids as mandatory first-line therapy. 2

• Azathioprine prevents unilateral uveitis from becoming bilateral and is the cornerstone of treatment 2, 3
• For severe eye disease (>2 lines of visual acuity loss or retinal vasculitis/macular involvement), add either infliximab or cyclosporine A to the azathioprine-corticosteroid combination; alternatively, interferon-alpha with or without corticosteroids can be used. 2
• This aggressive approach has reduced vision loss from 75% to 20% of affected eyes 3

Neurological Involvement (Neurobehçet's Disease)

For acute parenchymal Neurobehçet's disease, initiate high-dose intravenous methylprednisolone followed by oral prednisolone, combined with azathioprine 2.5 mg/kg/day as the preferred steroid-sparing agent from the outset. 1

• Taper oral steroids by 5-10 mg every 10-15 days, targeting a maintenance dose of 5-10 mg/day over 6-12 months 1
• Methotrexate (15-25 mg/week) serves as an alternative steroid-sparing agent if azathioprine is not tolerated 1
• For dural sinus thrombosis specifically, high-dose corticosteroids alone are the primary treatment 1
• TNF-alpha inhibitors, particularly infliximab, are recommended for refractory or severe cases failing conventional therapy 1
• Critical pitfall: Never use cyclosporine A in patients with CNS involvement due to significant neurotoxicity risk 2, 1

Vascular Involvement

For acute deep vein thrombosis, use immunosuppressive agents (corticosteroids combined with azathioprine, cyclophosphamide, or cyclosporine A) rather than anticoagulation. 2

• For pulmonary and peripheral arterial aneurysms, cyclophosphamide combined with corticosteroids is recommended 2
• Critical pitfall: Do not use anticoagulants, antiplatelet agents, or antifibrinolytic agents for venous thrombosis in Behçet's disease 2
• Rationale: Venous thrombi adhere to vessel walls without causing emboli, and pulmonary embolism is rare despite high venous thrombosis frequency 2
• Additional concern: Coexisting pulmonary arterial aneurysms may cause fatal bleeding if anticoagulated 2, 4

Gastrointestinal Involvement

Before considering surgery (except emergencies), trial sulfasalazine, corticosteroids, azathioprine, TNF-alpha antagonists, or thalidomide sequentially for gastrointestinal ulcers. 2

• Gastrointestinal ulcers in Behçet's are deep and penetrating, predominantly affecting the terminal ileum, ileocecal region, and colon with high perforation risk 2
• Sulfasalazine specifically improves gastrointestinal vasculitis 3

High-Risk Populations Requiring Aggressive Treatment

Young men with early disease onset require more aggressive immunosuppression and closer monitoring due to higher risk of severe disease and major organ involvement. 1, 5

• This demographic faces the highest risk of severe cardiac, vascular, and neurological complications 1, 4

Refractory Disease Management

For patients failing conventional immunosuppression across any organ system, TNF-alpha inhibitors (infliximab or adalimumab) represent the next therapeutic step. 1, 6

• Screen for tuberculosis before initiating anti-TNF therapy 4
• Infliximab combined with azathioprine shows particular promise for severe or refractory cardiac involvement 4

Long-Term Management Considerations

Disease manifestations typically ameliorate over time, allowing for treatment tapering and potential discontinuation in stable patients. 1, 5

• Regular monitoring of inflammatory markers and organ-specific assessments remains essential even during remission 1, 5
• Patients with history of major organ involvement require continued surveillance despite symptom improvement 5
• Medication non-compliance can trigger disease flares and organ damage despite the natural tendency toward improvement 5